


32nd
Meeting of

the European Society of
**PAEDIATRIC
CLINICAL
RESEARCH**

24-25 May 2024
Opatija, Croatia

TABLE OF CONTENTS

WELCOME	3
ORGANIZATION	4
PRACTICAL INFORMATION	4
PROGRAM	5
SPONSORS & PARTNERS	11



WELCOME LETTER



Dear colleagues and friends,

We are pleased to welcome you to the 32nd Meeting of the European Society of Paediatric Clinical Research (ESPCR) which takes place in Opatija, Croatia, May 24-25, 2024.

The successful 31st ESPCR Meeting in Budapest confirmed that we need to connect now more than ever. Our two-day meeting will once again bring together young paediatricians, researchers and leaders in the field from all over Europe, and provide a lively platform for the dissemination of our knowledge and views in paediatrics without borders.

Faithful to our tradition, conference participation is free of charge and reflects our commitment to free and timely knowledge sharing. The scientific programme consists of state-of-the-art lectures, oral and poster presentations on issues of interest for paediatrics, and a workshop on pharmacogenomics in the era of next-generation sequencing.

It is our great pleasure to welcome you in a creative and engaging setting at the beautiful city of Opatija. We are sure that this event will bring the fantastic opportunity to strengthen old friendships and make new connections in our strong community.

We are looking forward to meeting you again.

On behalf of the Organising Committee,
Dr Jelena Roganović

ORGANIZATION

Organizer

Croatian Pediatric Society of the Croatian
Medical Association
Children's Hospital Zagreb
Faculty of Biotechnology and Drug
Development University of Rijeka

Conference venue

Congress Center Conference Park 25/7
Amadria Park Grand hotel 4 opatijska cvijeta
Ul. Nikole Tesle 5, HR-51410 Opatija

Committees

Radvan Urbanek – Honorary Chair

Scientific Committee

Goran Roić – Chair
Jelena Roganović
Nataša Marčun Varda
Attila Szabo
Hana Hrstkova
Ludmila Podracka
Jan Lebl

Organizing Committee

Jelena Roganović – Chair
Anđelka Radojčić Badovinac
Sonja Pavlović
Iva Hojsak
Nada Krstovski
Jelica Predojević Samardžić
Silvije Šegulja

SCIENTIFIC PROGRAM

TOPICS

- Bioinformatics in pediatric and adolescent medicine
- Basic science
- Child – and adolescent psychiatry
- Epidemiology in pediatrics
- Neonatology
- Pediatric allergology
- Pediatric cardiology
- Pediatric dentistry
- Pediatric dermatology
- Pediatric endocrinology
- Pediatric gastroenterology
- Pediatric hematology
- Pediatric immunology
- Pediatric emergency medicine and critical care
- Pediatric nephrology
- Pediatric neurology
- Pediatric oncology
- Pediatric pulmonology
- Pediatric rheumatology
- Pediatric surgery
- Translational medicine
- Other

PRACTICAL INFORMATION

Registration opening hours

Location: 1st floor Congress Center Conference Park 25/7
Friday, May 24: 09:00-18:00
Saturday, May 25: 09:30-13:00

PROGRAM



DAY 1: FRIDAY, 24 MAY 2024

1ABC HALL

09:00-10:00 Registration

**10:00-10:20 Opening ceremony
Welcome remarks**

Jelena Roganović - Organizing Committee

Goran Roić - Children's Hospital Zagreb

Anđelka Radojčić Badovinac - Faculty of Biotechnology and Drug Development Rijeka

Aida Mujkić - Croatian Pediatric Society

**10:20-10:50 Plenary lecture
Sonja Pavlović: Genomics as a Basis for Precision Medicine**

**10:50-12:00 Scientific Session I
Chairs: Nataša Marčun Varda, Silvije Šegulja**

Mirjam Močnik

Superoxide dismutase and Interleukin-2 receptor in pediatric patients with chronic kidney disease or hypertension

Sonja Golob Jančič

Serum and urine uromodulin determination in children with chronic kidney disease

Beáta Szebeni

Extracellular vesicles originated from mesenchymal cells of peritoneal dialysate reduce fibrosis

Mirjam Močnik

Salusin- β in children with chronic kidney disease or hypertension

Rana Ibrahim

Cord blood levels of C-peptide and glycemia in gestational diabetes mellitus

Eszter Muzslay

Transient antithyroid autoantibody elevation in children with type 1 diabetes mellitus

**11:50-12:50 Scientific Session II
Chairs: Petr Jabandžiev, Domonkos Pap**

Dorottya Antics

The first 5 years of the pediatric Home Ventilation Program (OLP) in a Hungarian centre

Bertalan Horváth

When the heart skips a beat: electrolyte disturbances caused by enteritis: case report

Vanda Pal

Assessment of neurodevelopmental outcome in infants born during the COVID-19 pandemic

Andrea Xue

Cystic fibrosis neonatal screening in Hungary. A single center evaluation of the first two years

Silvije Šegulja

Predictive model of repeated episodes of febrile neutropenia in children with cancer

Nuša Matijašić Stjepović

Managing refractory and relapsed Hodgkin lymphoma: our 5-year experience

13:00-14:00 Lunch

14:00-15:00 Scientific Session III
Chairs: Branka Zukić, Kariofyllis Karamperis

Alexandra Gaál Kovalčíková

The role of neutrophil extracellular traps in the animal model crystal-induced chronic kidney disease

Timea Medveczki

Fluvoxamine, a Sigma-1 receptor agonist, is a new and innovative therapy for glaucoma

Domonkos Pap

PARK7 as a new therapeutic target in pulmonary fibrosis

Apor Veres-Szekely

Optimization of Sirius Red-based microplate assay to investigate collagen production in vitro

Tamas Lakat

Sigma-1 receptor agonist mitigates bleomycin-induced pulmonary fibrosis in mice

Eszter Levai

Molecular and functional characterization of the peritoneal mesothelium, a major barrier for small solute transport

15:00-15:20 Jelena Roganović
Iron deficiency anemia in children (SALVUS)

15:20-16:00 Coffee break

16:00-18:00 PharmGenHUB Workshop „Bioinformatics tools for next-generation sequencing analysis in pharmacogenomics“

20:00-23:00 Social event with the conference dinner

DAY 2: SATURDAY, 25 MAY 2024

1ABC HALL

10:00-10:50 Scientific Session IV
Chair: Jelena Roganović, Nada Rajačić

Simona Ivančan

Integrative transcriptomic profiling of the Wilms tumor

Mia Radošević

Panhypopituitarism caused by a suprasellar germinoma: case report

Dora Šimić Crnjac

Transient erythroblastopenia of childhood and COVID-19 infection: case report

Tomaž Prelog

The influence of cytotoxic drugs on the immunophenotype of blast cells in pediatric B-precursor acute lymphoblastic leukaemia

10:50-12:50 Poster Session
Chairs: Nada Krstovski, Jelica Predojević Samardžić

- PI-01 Bojan Ristivojević**
Can NUDT15 be pharmacogenetic or pharmacotranscriptomic marker for 6-mercaptopurine in children with acute lymphoblastic leukemia in Serbia
- PI-02 Klementina Črepinšek**
Genetic alterations in a consecutive childhood B-ALL cohort treated on ALL IC-BFM 2009 protocol in Slovenia
- PI-03 Irena Marjanović**
Germline variants in cancer predisposition genes in pediatric patients with central nervous system tumors
- PI-04 Izabela Kranjčec**
Febrile neutropenia in pediatric acute lymphoblastic leukemia: has bacterial landscape changed over the years?
- PI-05 Nada Rajačić**
Hepatic sinusoidal obstruction syndrome as a complication of a pediatric solid tumour treatment – a single-centre experience
- PI-06 Domagoj Buljan:**
Selumetinib therapy in NF1 patients with progressive plexiform neurofibroma
- PI-07 Sonja T. Marinković**
Multisystem Langerhans cell histiocytosis in a 17-month-old boy: case report
- PI-08 Maja Pavlović**
Gastrointestinal complications in children undergoing abdominal and/or pelvic radiotherapy for solid tumours

- PI-09** **Sara Lulić Kujundžić**
Psychological presentation of a girl with high-risk abdominal neuroblastoma
- PI-10** **Marta Despotović**
A novel likely pathogenic sequence variant in the RUNX1 gene as the cause of congenital thrombocytopenia: case report
- PI-11** **Neža Salobir**
Appendiceal neuroendocrine tumors in children and adolescents
- PI-12** **Iva Kapetanović**
Malignant testicular tumor in a sixteen-month old boy: case report
- PI-13** **Klara Vranešević**
Spitzoid melanoma: case report
- PI-14** **Sonja Pavlović**
Prenatal origin of pediatric B-cell precursor acute lymphoblastic leukemia: tracing back leukemia to birth using leukemic clone-specific immunoglobulin heavy chain rearrangements
- PI-15** **Anita Skakic**
Investigating the genetic complexity of neutropenia in pediatric patients with Glycogen storage disease Ib: a modifier gene perspective
- PI-16** **Ana Đorđević**
Inherited thrombophilia and risk of thrombosis in children with cancer: a single-center experience
- PI-17** **Nada Krstovski**
Treatment of Hodgkin Lymphoma in childhood: 10-years experience with PET-based protocols
- PI-18** **Marina Anđelković**
Characterization of 16 novel genetic variants in genes associated with pediatric epilepsy: implications for targeted therapeutic strategies
- PI-19** **Marina Jelovac**
Population pharmacogenomics of immunosuppressive and aminosalicylate therapy: potential for therapy optimization in Serbian paediatric inflammatory bowel disease patients
- PI-20** **Đorđe Pavlović**
Exploring variation in Adhesion G protein-coupled receptor genes: Insights from genomic datasets of pediatric rare disease cases in Serbia
- PI-21** **Martin Jouza**
Sacrococcygeal teratoma: a single-center experience
- PI-22** **Kristel Klaassen**
Molecular basis of phenylketonuria in Serbian pediatric cohort

12:50-13:00 **Closing remarks**
Best presentation award
ESCPR 2025

13:00-14:00 **Lunch**



Project PharmGenHUB
is supported by EU
HORIZON-WIDERA-2021-ACCESS-02- 01
GA 101059870 (2022-2025)



32nd Meeting of the European Society of Paediatric Clinical Research (ESPCR) Opatija, Croatia, 24 May 2024

PharmGenHUB Workshop

Bioinformatics tools for next-generation sequencing analysis in pharmacogenomics

16:00- 16:20 Project PharmGenHUB: Population pharmacogenomics in the Western Balkans

Branka Zukić

Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Belgrade, Serbia

16:20 – 16:40 Health Economics in Personalised Medicine: Results from the PREPARE clinical study

Christina Mitropoulou

The Golden Helix Foundation, London, UK

United Arab Emirates University, College of Medicine and Health Sciences, Department of Genetics and Genomics, Al-Ain, Abu Dhabi, UAE;

16:40-17:00 Deciphering the concept of population pharmacogenomics and its clinical impact: A worldwide spectrum

Kariofyllis Karamperis

The Golden Helix Foundation, London, UK

University of Patras, Department of Pharmacy, Patras, Greece

17:00-17:10 Next Generation Sequencing (NGS) Technology

Branka Zukić

Institute of Molecular Genetics and Genetic Engineering University of Belgrade, Belgrade, Serbia

17:10 -17:20 Bioinformatic preprocessing of NGS data: from raw data to genetic variants

Nikola Kotur

Institute of Molecular Genetics and Genetic Engineering University of Belgrade, Belgrade, Serbia

17:20- 17:30 Bioinformatics resources in pharmacogenomics research

Nikola Kotur

Institute of Molecular Genetics and Genetic Engineering University of Belgrade, Belgrade, Serbia

17:30-17:40 Interpretation of NGS Results: analysis of pharmacogenomics variants

Sonja Pavlović,


Institute of Molecular Genetics and Genetic Engineering University of Belgrade, Belgrade, Serbia

17:40-18:00 Discussion

Coordinator

IMGGI

Institute of Molecular Genetics
and Genetic Engineering
University of Belgrade
Belgrade, Serbia



EU partners



UNIVERSITY OF
PATRAS
ΠΑΝΕΠΙΣΤΗΜΙΟ ΠΑΤΡΑΣ

University of Patras
Department of Pharmacy, Patras, Greece (UPAT)



Univerza v Ljubljani

University of Ljubljana
Faculty of Medicine, Ljubljana, Slovenia (UL)



University of Trieste, Department of Medicine
Surgery and Health Sciences, Trieste, Italy (UT)

WB partners

University Clinical Centre of Republic of Srpska, Banjaluka, BH
University of Sarajevo, Institute for Genetic Engineering and Biotechnology, Sarajevo, BH
Department of Pediatrics, Clinical Hospital Centre Rijeka, Rijeka, Croatia
Center for Medical Genetics and Immunology, Clinical Center of Montenegro, Podgorica, Montenegro
University Clinic for Pediatrics, Medical Faculty of Skopje, Skopje, Northern Macedonia

SPONSORS



PARTNERS



Naša najbolja zaštita za dojenčad rođenu carskim rezom



HiPP BIO COMBIOTIK®
potiče stvaranje uravnotežene
crijevne mikrobiote.



Beba: Anna, 8 mjeseci

**EVIDENCE-
BASED
APPROACH**

NOVO- meta-analiza dokazuje:
L. fermentum CECT5716 smanjuje učestalost
gastrointestinalnih infekcija za 73%.¹

Važna informacija:

Majčino mlijeko je najbolja hrana za dijete. Mliječni pripravci za dojenčad trebali bi se davati samo po preporuci zdravstvenih djelatnika.
¹ Blanco-Rojo R et al. Front. Pediatr. 2022; 10: 906924.
doi: 10.3389/fped.2022.906924



Za više informacija o carskim rezovima
skenirajte QR kod ili posjetite:
hipp.com/hcp/caesarean-section



ONKOLOŠKE BOLESTI

**HIPERTENZIJA
ANGINA PEKTORIS
SRČANO POPUŠTANJE**

**KRONIČNA VENSKA BOLEST
HEMOROIDALNA BOLEST**

DIJABETES

DEPRESIJA

**PREDANI SMO TERAPEUTSKOM
NAPRETKU, KAKO BISMO
ISPUNILI CILJEVE LIJEČENJA
BOLESNIKA**





Evrysdi[®]

risdiplam

Omogućava dojenčadi, djeci, tinejdžerima i odraslima:

- Trajno poboljšanje ili stabilizaciju motoričkih funkcija^{1,2,3}
- Očuvanje sposobnosti gutanja i hranjenja^{1,2,3}
- Dosljednu ekspresiju SMN proteina kroz cijeli središnji živčani sustav i u perifernim tkivima⁴
- Tretman koji se dobro podnosi uz svakodnevno doziranje kod kuće^{1,2,3}

15 000+
osoba sa
SMA liječeno
u svijetu*

*Evrysdi March 2024 Data On File (DOF)

Evrysdi je indiciran za liječenje spinalne mišićne atrofije (SMA) uzrokovane mutacijom na kromosomu 5q u bolesnika koji imaju kliničku dijagnozu SMA tipa 1, tipa 2 ili tipa 3 ili jednu do četiri kopije gena *SMN2*.

▼ Ovaj je lijek pod dodatnim praćenjem. Time se omogućuje brzo otkrivanje novih sigurnosnih informacija. Od zdravstvenih radnika se traži da prijave svaku sumnju na nuspojavu za ovaj lijek. Upute za prijavljivanje dostupne su na www.halmed.hr.

VAŽNE INFORMACIJE O SIGURNOSTI Kontraindikacije: Preosjetljivost na djelatnu tvar ili neku od pomoćnih tvari navedenih u dijelu 6.1 Sažetka opisa svojstava lijeka **Posebna upozorenja i mjere opreza pri uporabi- Potencijalna embriofetalna toksičnost** U ispitivanjima na životinjama opažena je embriofetalna toksičnost (vidjeti dio 5.3 Sažetka opisa svojstava lijeka). Bolesnike reproduktivne dobi treba upozoriti na rizike te da se mora koristiti visokoučinkovita kontracepcija tijekom liječenja i još najmanje 1 mjesec nakon posljednje doze u žena odnosno 4 mjeseca nakon posljednje doze u muškaraca. Prije uvođenja lijeka Evrysdi u bolesnica reproduktivne dobi treba potvrditi status trudnoće (vidjeti dio 4.6 Sažetka opisa svojstava lijeka). **Mogući učinci na plodnost muškaraca** Temeljem opažanja iz ispitivanja na životinjama, bolesnici ne smiju donirati spermu tijekom liječenja i još 4 mjeseca nakon posljednje doze lijeka Evrysdi. Prije uvođenja liječenja s bolesnicima reproduktivne dobi treba razgovarati o strategijama očuvanja plodnosti (vidjeti dijelove 4.6 i 5.3 Sažetka opisa svojstava lijeka). Učinci lijeka Evrysdi na plodnost muškaraca nisu se ispitivali u ljudi. **Toksičnost za mrežnicu** Učinci lijeka Evrysdi na strukturu mrežnice opaženi u nekliničkim ispitivanjima sigurnosti nisu primijećeni u kliničkim ispitivanjima u bolesnika sa SMA-om. Međutim, dugoročni podaci još su uvijek ograničeni. Dugoročan klinički značaj tih nekliničkih nalaza stoga nije ustanovljen (vidjeti dio 5.3 Sažetka opisa svojstava lijeka). **Pomoćne tvari Izomalt** Evrysdi sadrži izomalt (2,97 mg po ml). Bolesnici s rijetkim nasljednim poremećajima ne-podnošenja fruktoze ne bi smjeli uzimati ovaj lijek. **Natrij** Evrysdi sadrži 0,375 mg natrijeva benzoata po ml. Natrijev benzoat može pojačati žuticu (žutilo kože i očiju) u novorođenčadi (do 4 tjedna starosti). Evrysdi sadrži manje od 1 mmol natrija (23 mg) po dozi od 5 mg, tj. zanemarive količine natrija. **Doziranje** Preporučena doza lijeka Evrysdi za primjenu jedanput na dan određuje se prema dobi i tjelesnoj težini. Evrysdi se uzima peroralno jedanput na dan nakon obroka, svaki dan u približno isto vrijeme. Režim doziranja prema dobi i tjelesnoj težini Preporučena dnevna doza < 2 mjeseca, Q15 mg/kg, 2 mjeseca do < 2 godine 0,20 mg/kg ≥ 2 godine (< 20 kg) 0,25 mg/kg ≥ 2 godine (≥ 20 kg) 5 mg. Nije se ispitivalo liječenje dnevnom dozom većom od 5 mg.

Najčešće nuspojave U bolesnika sa SMA om s nastupom u dojenačkoj dobi najčešće nuspojave opažene u kliničkim ispitivanjima lijeka Evrysdi bile su vrućica (54,8%), osip (29,0%) i proljev (19,4%). U bolesnika sa SMA om s nastupom u kasnijoj dobi najčešće nuspojave opažene u kliničkim ispitivanjima lijeka Evrysdi bile su vrućica (21,7%), glavobolja (20,0%), proljev (16,7%) i osip (16,7%). Navedene nuspojave javljale su se bez prepoznatljivog kliničkog ili vremenskog obrasca te su se općenito povlačile unatoč na-stavku liječenja i u bolesnika koji su imali SMA s nastupom u dojenačkoj dobi i u onih oboljelih od SMA s nastupom u kasnijoj dobi. Vidjeti i dio 5.3 Sažetka opisa svojstava lijeka za učinke lijeka Evrysdi opažene u nekliničkim ispitivanjima.

Prijavljivanje sumnji na nuspojavu Nakon dobivanja odobrenja lijeka važno je prijavljivanje sumnji na njegove nuspojave. Time se omogućuje kontinuirano praćenje omjera koristi i rizika lijeka. Od zdravstvenih radnika se traži da prijave svaku sumnju na nuspojavu lijeka putem nacionalnog sustava prijave nuspojava: Agencija za lijekove i medicinske proizvode (HALMED) Internetska stranica: www.halmed.hr ili potražite HALMED aplikaciju putem Google Play ili Apple App Store trgovine

Za cjelovitu informaciju molimo pogledati zadnji odobreni Sažetak opisa svojstava lijeka, dostupan na mrežnim stranicama www.halmed.hr.

SAMO ZA ZDRAVSTVENE RADNIKE

Međunarodni naziv djelatne/ih tvari: risdiplam, Broj odobrenja: EU/1/21/1531/001, Nositelj odobrenja: Roche Registration GmbH, 79639 Grenzach-Wyhlen, Njemačka, Lijek se izdaje na recept. Sastavni dio ovog materijala je cjelokupni odobreni Sažetak opisa svojstava lijeka, dostupan na mrežnim stranicama www.halmed.hr. M-HR-00001778 Datum izrade svibanj 2024.

1. Sažetak opisa svojstava lijeka Evrysdi, dostupan na www.halmed.hr; 2. Darras BTet et al. N Engl J Med 2021;385:427-35.; 3. Mercuri E et al. Lancet Neurol 2022; 21: 42-5; 4. Poirier A et al. Pharmacol Res Perspect. 2018;e00447



CONVENTUS
credo

U ORGANIZACIJI
KONGRESA
OD 2006.

Conventus Credo d.o.o. Bogišićeva 2, 10000 Zagreb, Hrvatska
MB 2102510 OIB 94766180676 ID HR-AB-01-080571631
Tel +385 1 4854 696 Fax +385 1 4854 580 Mail info@conventuscredo.hr
www.conventuscredo.hr